| Overview |
| bs-10176R-PE |
| PRAS40 Polyclonal Antibody, PE Conjugated |
| WB |
| Human |
| Mouse, Rat, Cow, Sheep, Pig, Horse |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PRAS40 |
| 161-256/256 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 84335 |
| Q96B36 |
| Cytoplasm |
| AKT1 substrate 1 (proline rich); AKT1 substrate 1; AKT1-S1; AKT1S-1; AKT1S 1; AKT1S1; Lobe; PRAS 40; PRAS-40; PRAS40; Proline rich akt substrate; 40 kDa proline rich AKT substrate; 40 kDa proline-rich AKT substrate; AKT1 S1; AKT1 substrate 1; AKTS1_HUMAN; MGC2865; PRAS40; Proline rich Akt substrate 40 kDa; Proline-rich AKT1 substrate 1. |
| Proline Rich Akt Substrate (PRAS40) is a 40 kDa substrate of Akt. Akt and PRAS40 can be found in the phosphoinositide 3 kinase (PI3K) pathway, which plays a role in glucose uptake, cell growth, and apoptosis inhibition. PRAS40 is a 14-3-3 binding protein that reacts with insulin, but whose precise function is not yet known. It may bind SH3 and WW domain containing proteins resulting in a change of function. Activated Akt phosphorylates PRAS40 on threonine 246. Mutation of PRAS40 threonine 246 has been shown to be apoptotic. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz